GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Institutional Ownership

Theravance Biopharma (FRA:0TB) Institutional Ownership : 25.90% (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Theravance Biopharma's institutional ownership is 25.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Theravance Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Theravance Biopharma's Float Percentage Of Total Shares Outstanding is 50.94%.


Theravance Biopharma Institutional Ownership Historical Data

The historical data trend for Theravance Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Institutional Ownership Chart

Theravance Biopharma Historical Data

The historical data trend for Theravance Biopharma can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 31.76 31.93 30.29 27.76 28.28 28.47 28.90 28.02 26.06 25.90

Theravance Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Theravance Biopharma (FRA:0TB) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines